3 ms·
>The -mabs are often denied because they really are expensive to make. Source? According to the HHS via Washington Post[1], many doses of monoclonal antibodies
by hammock 5y ago
>The -mabs are often denied because they really are expensive to make.
Source? According to the HHS via Washington Post[1], many doses of monoclonal antibodies have already been made, but only 20% of those distributed have been used, with 80% sitting on a shelf. The article suggests a few reasons for the lack of use, but it does not mention cost to make them.
[1]https://archive.fo/IHK4J https://archive.fo/IHK4J
- kragen 5y agoIt says 0.378 million doses have been distributed to healthcare facilities in the US. There have been 58 million confirmed cases in the US, 0.62 million new cases yesterday and 0.56 million new cases the day before. If they were to give those unallocated doses to every new covid case, they would be gone in 12 hours. So they are not abundant; they are scarce. Not enough are being made. It is true that I don't know how much Regeneron and Lilly are spending on making them, or how much they are getting paid, but monoclonal antibodies are usually very expensive, and I infer from the production levels that the expense is high enough that they don't have ten million doses sitting around just waiting to ship out.